The US Food and Drug Administration (FDA) has granted approval for Novo Nordisk's Wegovy (semaglutide 2.4 mg) for lowering cardiovascular risks in adults with established cardiovascular disease (CVD) who are overweight or obese.
UK-based biotechnology company IsomAb has secured £7.5m (approximately $9.4m) in a seed funding round to expedite the development of its lead candidate targeting peripheral arterial disease.
Innovent Biologics has signed a partnership agreement with Sanegene Bio to jointly develop an angiotensinogen (AGT) directed siRNA drug candidate, SGB-3908, to treat hypertension.
Amarin has entered into an exclusive marketing and commercialisation agreement with Neopharm for VAZKEPA in the State of Israel, Gaza, West Bank and the territories of the Palestinian Authority.
Eleven Therapeutics has entered into a research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics.
Clinical-stage biotechnology company Tenaya Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its gene therapy product candidate, TN-201.
Novartis has received positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), which recommended approval for the company’s Entresto (sacubitril/valsartan) to treat paediatric heart failure.
The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Rocket Pharmaceuticals’ RP-A501, an investigational adeno-associated virus (AAV)-based gene therapy to treat Danon Disease.
Biopharmaceutical company Quantum Genomics has signed an exclusive license and production agreement with Julphar to market and manufacture firibastat.
Merck (MSD) has agreed to acquire all the outstanding shares of Acceleron Pharma for $11.5bn in cash.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.